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Abstract
Gasdermin-like (GSDML) belongs to the gasdermin-domain–containing protein family (GSDMDC family) that is in-
volved in carcinogenesis and hearing impairment. However, the role of GSDML in carcinogenesis remains unclear.
In this study, we identified four isoforms of GSDML gene. The primary and longest isoform GSDML1 is widely ex-
pressed in human cancer cell lines. GFP-GSDML1 fusion protein was localized predominantly in the nucleus of hu-
man breast cancer MCF7 and cervical cancer HeLa cells but exclusively in the cytoplasm of hepatocellular carcinoma
HepG2 cells. Importantly, immunohistochemistry analysis showed that the GSDML protein in the nuclei is expressed
at a higher level in uterine cervix cancer tissues than in the adjacent cancer tissues and corresponding nonneoplastic
tissues. Such significance was not observed in hepatocellular carcinoma tissues. Ectopic expression of GSDML1
enhanced the growth of cultured cells, whereas inhibition of its endogenous expression decreased proliferation.
Furthermore, GSDML1 had significant effects on promoting bromodeoxyuridine incorporation in cells. However,
GSDML1 could neither promote malignant transformation nor gain the ability of colony formation or carcinogenic-
ity on nude mice. Collectively, these results suggest that GSDML can promote cell proliferation, and it might be
correlated with carcinogenesis and progression of uterine cervix cancer.
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Introduction
Gasdermin-domain–containing (GSDMDC) protein family, defined
by a conserved gasdermin domain, includes five members, namely,
DFNA5, DFNA5L, MLZE, GSDM, and GSDML [1–5]. The precise
function of gasdermin domain still remains largely unclear. A deletion/
insertion mutation of DFNA5 is associated with an autosomal domi-
nant nonsyndromic hearing impairment form [1]. A decrease in
DNFA5 mRNA expression level has also been found to contribute
to acquired etoposide resistance in melanoma cells [6]. The expression
of the DFNA5 gene can be strongly induced by p53, and ectopic ex-
pression of DFNA5 enhanced etoposide-induced cell death in the pres-
ence of p53 [7]. Moreover, DFNA5 has been identified as a target of
epigenetic inactivation in gastric cancer [8]. MLZE is one of the genes
whose expression is up-regulated during the acquisition of metastatic
potential in melanoma cells [3]. GSDM is predominantly expressed
in the upper gastrointestinal tract but is significantly suppressed in
human gastric cancer cells, suggesting that the loss of human GSDM
is required for the carcinogenesis of gastric tissue and that GSDM
possesses an activity adverse to malignant transformation [4,9]. As
human DFNA5L mRNA is widely expressed in human cancer tis-
sues, DFNA5L might also be implicated in malignant potential of
tumor cells [2]. As a new member of the GSDMDC family, the func-
tion of GSDML gene is still unknown, and needs further investi-
gation. Mouse Gsdm1-Gsdm2-Gsdm gene cluster was predicted to
be generated due to the triplication of mouse Gsdm gene, whereas
human GSDML gene was predicted to be generated due to duplica-
tion of GSDM gene. The rodent ortholog of human GSDML has not
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been identified so far. In addition, evolutionary recombination hot-
spot around the GSDML-GSDM locus was closely linked to the onco-
genomic recombination hotspot around the PPP1R1B-ERBB2-GRB7
amplicon. Because DFNA5, MLZE, GSDM, and DFNA5L have
been implicated in the development and progression of cancer,
GSDML was predicted to be associated with cancer [5], which lack
experimental evidence until now.
To investigate whether GSDML is involved in the development
or progression of some cancers, we have cloned and characterized
GSDML gene and analyzed expression level of GSDML protein in
uterine cervix cancer and hepatocellular carcinoma tissues by immu-
nohistochemistry. Furthermore, we explore the function of GSDML
by the overexpression or silence expression in various cell lines. Our
study showed that subcellular localization of GSDML may influence
its function of proliferation promotion and reveal the pathophysio-
logical role of GSDML up-regulation in uterine cervix cancer. To our
knowledge, this is the first study addressing the potential role for
GSDML in cell growth and carcinogenesis of uterine cervix cancer.
Materials and Methods
Cloning, Plasmid Construction, and Small Interference RNA
Human GSDML gene was amplified from human fetal liver cDNA
library (Clontech, Terra Bella, CA). Polymerase chain reaction (PCR)
was done using a pair of forward (5′-CCG CTC GAG CA ATG TTC
AGC GTA TTT G-3′) and reverse (5′-CGC GGA TCC TTA GGA
AGA GAC AGA GGT-3′) primers under the conditions of 94°C
(60 seconds), 55°C (60 seconds), and 72°C (1 minute 20 seconds) for
30 cycles. Plasmid constructs were produced by general molecular biol-
ogy procedures. The expression vector encoding green fluorescent pro-
tein (GFP) fusion GSDML protein was generated by inserting GSDML
into pEGFP-C1 vector (Clontech). GFP-tagged GSDML1-ΔNLS
(242–261aa, predicted nuclear localization signal) was constructed by
PCR and recombinant PCR, followed by subcloning into pEGFP-C1
vector. The expression vector forMyc-taggedGSDMLwas generated by
inserting the fragment into pcDNA3.1/Myc-His(+)C (Invitrogen,
Carlsbad, CA). All PCR-based constructions were verified by DNA se-
quencing. short hairpin RNA (shRNA)-GSDML (target sequence nt
578–596 GCCAAAGGGAAGTGACCAT) plasmid containing the
neo expression cassette reform from RNAi-Ready-pSIREN-DNR-
DsRed-Express (Clontech) as we have described previously [10]. The
small interfering RNA (siRNA) against GSDML1 were designed and
chemically synthesized (Shanghai GenePharma Co., Shanghai, China)
for targeting coding regions (nt 570–588) of the GSDML1 gene as
follows: siRNA-GSDML1 (5′-ACACAAGGGCCAAAGGGAAtt-3′
and 3′-tt UGUGUUCCCGGUUUCCCUU-5′). The sequence of
negative control siRNA was 5′-UUCUCCGAACGUGUCACGUtt-
3′ and 3′-ttAAGAGGCUUGCACAGUGCA-5′ (Cat. no. B01001;
Shanghai GenePharma Co.).
Generation of Anti-GSDML Antibody
Rabbit polyclonal anti-GSDML antibodies and mouse monoclo-
nal antibody were generated against epitopic peptides (64–168aa)
from the GSDML protein sequence. Using the pEGFP-GSDML
as template, PCR was performed with the following set of primers:
5′- CGC GGA TCC AT ACA GAT GGG GAC AAG TGG TTA G
-3′ and 5′- CCG CTC GAG TTC CTC CTT TAC CGT CTC
CAG A -3′. The PCR-amplified cDNA fragment was excised and li-
gated into the BamHI–XhoI sites of pET28c vector (Qiagen, Hilden,
Germany). The plasmid was transformed to Escherichia coli BL21-
CodonPlus (Stratagene, Cedar Creek, TX), and the expression of
the 6 × His-tagged GSDML was induced with 0.05 mM isopro-
pylthiogalactoside. The bacteria were lysed by sonication, and the
GSDML tagged with 6 × His was extracted from the insoluble pellet
with 8 M urea, 0.5 M NaCl, 5 mM imidazole, and 20 mM Tris–HCl
(pH 8.0). Extracted protein was applied to Talon resin and was eluted
with excess imidazole. White rabbits and BALB/c mouse were immu-
nized with the purified protein to produce polyclonal and monoclonal
antibodies, respectively. The polyclonal antibodies could detect dena-
tured GSDML 1, 2, 3, and 4 in immunoblots and the native protein
in immunohistochemistry. The monoclonal antibody could detect the
native protein in immunofluorescence experiments.
Cell Culture and Transfections
Cell lines HepG2, MCF7, T47D, Ishikawa, MGC803, N87,
HeLa, SW480, LoVo, SACC-83, ACC-2 [11], ACC-M, A549, Glc-
82, U2OS, HEK293, HEK293T, Chang, and CHO-K1 were cul-
tured at 37°C in an atmosphere of 5% CO2 in Dulbecco’s modified
Eagle’s medium (Hyclone, Logan, UT) containing 100 units/ml pen-
icillin, 100 μg/ml streptomycin sulfate, and supplemented with 10%
fetal bovine serum. H1299, HCT-15, HNE1, Jurkat, MOLT-4, K-
562, and HL-60 cells were maintained in RPMI 1640 medium with
10% fetal bovine serum. All mammalian cells were transfected using
Lipofectamine 2000 (Invitrogen). G418 was from Invitrogen and was
used to screen stable transfectants as we have described previously [12].
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Total RNA was extracted from the 16 indicated cell lines using
Trizol (Invitrogen). Reverse transcription–polymerase chain reaction
(RT-PCR) amplification was performed using SuperScript III (Invi-
trogen). The specific primers used in the PCR reactions were
GAPDH (forward primer 5′-GAAGGTGAAGGTCGGAGTC-3′,
reverse primer 5′-GAAGATGGTGATGGGATTTC-3′) and
GSDML (forward primer 5′-ATGCCGGCACTACACAACAG-3′,
reverse primer 5′-CACTTAGCGAGGGAGTTTAG-3′, amplifica-
tion from nt 144 to 809). Polymerase chain reaction was performed
under the conditions of 94°C (40 seconds), 55°C (40 seconds), and
72°C (50 seconds) for 30 cycles for GAPDH and for 35 cycles for
GSDML. The PCR products were separated in 2% agarose gels.
Western Blot Analysis
Cells were washed in PBS and lysed in modified lysis buffer [50 mM
Tris–Cl (pH 7.5), 150 mM NaCl, 1% (v/v) Tween-20, 0.2% NP-40,
and 10% glycerol] with freshly added protease inhibitor cocktail tablet
(Roche, Indianapolis, IN), 1 mM NaF, and 0.1 mg/ml PMSF as de-
scribed previously [12]. Western blot analysis was performed with anti-
GSDML rabbit polyclonal antibody or mouse monoclonal antibody
and then the appropriate secondary antibody, followed by detection
with SuperSignal chemiluminescence kit (Pierce, Rockford, IL).
Subcellular Localization Analysis
For subcellular localization analysis, GSDML 1, 2, 3, and 4 and
GSDML1-ΔNLS were cloned into the vector pEGFP-C1 as described
previously. The resulting GFP-GSDMLs and the GFP-GSDML1-
ΔNLS were transfected into MCF7 cells by Lipofectamine 2000.
Cells were incubated at 37°C for 24 hours before examination with
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a fluorescence microscope to determine the subcellular location. In
addition, HeLa and HepG2 cells were used to examine subcellular
localization of GFP-GSDML1. To explore subcellular localization
of endogenous GSDML, MCF7, HeLa, HepG2, and LoVo cells
were seeded in 35-mm plate and were analyzed by indirect immuno-
fluorescence. Cells were fixed in 4% paraformaldehyde for 10 min-
utes and then in 0.1% PBST (containing 0.5% Triton X-100) for
15 minutes. Further processing included incubating cells in 5%
BSA for 10 minutes before incubations with anti-GSDML mouse
monoclonal or rabbit polyclonal antibody for 3 hours at 37°C and
with flourescein isothiocyanate–conjugated goat antimouse or goat
antirabbit secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) at the dilution of 1:200 for 1 hour at room temperature.
Cells were analyzed in PBS when the nuclei were stained with Hoechst
33258 (Sigma, St. Louis, MO). Fluorescence images were captured
with a fluorescence microscope (Olympus, Tokyo, Japan) or a con-
focal microscope (Carl Zeiss, Jena, Germany). Furthermore, Myc-
GSDML1, 2, 3, and 4 were each transfected into MCF7 cells and
analyzed by indirect immunofluorescence with anti-Myc monoclonal
antibody to validate the localization results of GFP-GSDMLs.
Tissue Microarray Construction, Immunostaining, and
Statistics Analysis
Tissue microarrays of human uterine cervix cancer and hepato-
cellular carcinoma were purchased from Shaanxi Chao Ying Bio-
technology Co., Ltd., China. Each of the uterine cervix cancer and
hepatocellular carcinoma tissue microarrays was composed of 21 cou-
ples of cancer tissues, adjacent cancer tissues, and corresponding non-
neoplastic tissues. Data about tumor histologic type and differentiation
have been recorded prospectively for these specimens.
Immunohistochemistry analysis was performed with a standard
avidin/biotin peroxidase method with an anti-GSDML rabbit poly-
clonal antibody (1:200 dilution). Briefly, 4-μm-thick array sections
were dewaxed with xylene (twice for 10 minutes), rehydrated through
graded alcohol (three times for 10 seconds), and immersed in meth-
anol containing 0.3% hydrogen peroxide for 10 minutes to block
endogenous peroxidase activity. Heat-induced epitope retrieval con-
sisting of 2 minutes of microwave treatment at high power in pH
6.0 citrate buffer (0.01 M) was necessary with the anti-GSDML rabbit
polyclonal antibody. Endogenous avidin/biotin binding was blocked
using an avidin/biotin blocking kit (Vector Laboratories, Servion,
Switzerland), and sections were treated with 100 μl of normal rabbit
serum for 10 minutes to block nonspecific binding of the primary
antibody. Sections were then incubated with 100 μl of primary anti-
body overnight at 4°C. Primary antibody was omitted from negative
control sections, which were incubated in dilute normal rabbit se-
rum. After washing with 0.1% Tween–PBS twice, sections were in-
cubated with 100 μl of biotinylated antirabbit immunoglobulin
(DAKO Ltd., Glostrup, Denmark) diluted 1:100 for 12 minutes,
followed by 100 μl of preformed streptavidin biotin/horseradish
peroxidase complex (DAKO) for 12 minutes at room temperature.
Staining was finally developed using 3,3′-diaminobenzidine tetra-
hydrochloride (DAKO). The slides were finally counterstained with
hematoxylin and washed before passing through serial alcohol and
xylene baths. Slides were finally dried and mounted with DPX (a
mixture of disterene, plasticizer, and xylene; Sigma).
Evaluation of the staining was carried out by two pathologists,
who were blinded to the clinicopathologic data, with a consensus de-
cision in all cases. For each antigen, tumors were classified into three
groups with regard to staining intensity: negative, weakly positive,
and positive. All tissue samples on the array were used for compar-
isons of GSDML overexpression. Contingency table analysis and
Fisher tests were used to study the relationship between cancer, ad-
jacent cancer tissues, corresponding nonneoplastic tissues with can-
cers, and GSDML expression.
Measurement the Cell Growth
To study the effect of GSDML gene on cell proliferation, the
pcDNA3.1(+) vector control and the pcDNA3.1(+)/GSDML1 mam-
malian expression construct were transfected into Chinese hamster
ovarian cells (CHO-K1). G418 was used to obtain the neomycin-
resistant transformants that indicated that the vector was present
in the CHO-K1 cells. Control pooled clones and three individual
GSDML1 clones were designed for the experiments in this study.
CHO-K1 cells in the log phase were trypsinized and seeded in 24-
well plates at a density of 5 × 103 cells/well. Cell proliferation was de-
tected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyl tetrazolium
bromide (MTT) colorimetric method every 24 hours in four wells
for six successive days to compose the growth curve in vitro. The
units of absorption (UA) were measured with Microplate Photometer
Analyzer (Bio-Tek, Winooski, VT) at a wavelength of 490 nm. In
addition, HeLa and HepG2 cells were seeded in 96-well plates at a
density of 5 × 103 cells/well and were transfected with negative con-
trol siRNA and GSDML1-siRNA, respectively. Cell growth curve
was measured as described previously.
Cell Proliferation Assay
For measure DNA synthesis rates, the pcDNA3.1(+) vector con-
trol and three independent pcDNA3.1(+)/GSDML1 stably trans-
fected CHO-K1 cell strains were seeded in 96-well plates at a
density of 1 × 104 cells/well for 24 hours. Incubation of cells with
bromodeoxyuridine (BrdU) for 18 hours followed by immunodetec-
tion of incorporated BrdU label. The labeling solution was removed,
and 200 μl of FixDenat (Merck KGaA, Darmstadt, Germany) solu-
tion was added and incubated for 30 minutes at room temperature.
After removing FixDenat, 100 μl of anti–BrdU-POD solution was
added and incubated for 90 minutes at room temperature. After
washing three times with 300 μl/well of washing buffer, the 100 μl
of tetramethylbenzidine (TMB) substrate solution (Boshide Tech,
Ltd., Wuhan, China) was added and incubated for 10 minutes at
room temperature until color development was sufficient for photo-
metric detection. The reaction was stopped with the addition of a
TMB stop solution (100 μl). The absorbance of the samples was
measured with an ELISA reader at 450 nm within 5 minutes after
adding the stop solution.
Clone Formation Test
HeLa and HepG2 cells were seeded in 35-mm plates and transfected
with control shRNA and GSDML shRNA plasmid containing the neo
expression cassette and selected with 800 mg/ml G418 for 20 days and
were then fixed with methanol and stained by 0.2% crystal violet.
Colony-Forming Efficiency in Soft Agar
One milliliter of 0.6% agarose in high-fertility culture medium
was allowed to solidify in 35-mm culture dishes. These were overlaid
with 1 ml of 0.3% agarose containing 1 × 104 cells/ml in middle-
fertility culture medium.Onemilliliter of low-fertility culture medium
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was added to each well the next day. Cells from different stably trans-
fected cell strains were incubated for 2 weeks at 37°C. The cell colonies
(more than 15 cells) were counted under the microscope. The average
of three independent experiments was shown.
Tumorigenesis Ability on Nude Mice Models
Eight of 4-week-old NIH athymic mice (purchased from the Ins-
titute for Experimental Animals, Peking Union Medical College,
China) were maintained in the pathogen-free environment and di-
vided into two groups. Each group consisted of four animals receiving
pcDNA3.1(+) empty vector control and pcDNA3.1(+)/GSDML1
stably transfected CHO-K1 cell line separately. The cell suspensions
were made in Hank’s balanced salt solution, and 1 × 107 viable cells/
0.2 ml was injected subcutaneously in the back of the nude mice.
Results
Bioinformatic Analysis of GSDML
The full-length cDNA (Figure 1A) was 1518-bp long (GenBank
Accession No. AK000409) and contained an open reading frame from
nucleotide 72 to nucleotide 1283 capable of encoding a 403–amino
acid polypeptide with a predicted molecular mass of 46 kDa. The
Figure 1. Identification and characterization of GSDML. (A) Nucleotide sequence and deduced amino acid sequence of the GSDML. Top
indicates nucleotide sequence; bottom, predicted amino acid sequence; numbers, the nucleotide residues and the amino acid residues.
The 5′ and 3′ untranslated regions are lower-case character. The initiating ATG codon (nucleotides 72–74) is preceded by one in-frame
TGA stop codon. The coding sequence ends at nucleotide 1284 followed by TAA. The three codons and a classic polyadenylation signal
are boxed. The amino acids comprising the gasdermin domain are in shaded. The sequence of a putative nuclear localization signal is
underlined and six basic amino acids (K/R) are in bold. (B) The recombinant plasmids of human GSDML from human fetal liver cDNA
library were identified by restriction enzyme analysis. pEGFP-C1 empty vector (lane 2) and six recombinant plasmids selected randomly
(lanes 3–8) were digested with restriction enzymes (BamHI, XhoI). (C) Expression detection of GSDML isoforms in 15 human cancer cell
lines and in human normal HEK293 cell by RT-PCR. ddH2O was used as the negative control of template. β -Actin levels were analyzed
and shown as an internal control. (D) Characterization of anti-GSDML rabbit polyclonal antibody and mouse monoclonal antibody.
Whole-cell extracts were prepared from CHO-K1 cells expressing pcDNA3.1(+) empty vector and pcDNA3.1(+)/GSDML 1, 2, 3, and
4. These samples were separated on 15% SDS-PAGE, probed with anti-myc mouse monoclonal antibody (left), anti-GSDML rabbit poly-
clonal antibody (middle), or anti-GSDML mouse monoclonal antibody (right). (E) Expression of endogenous GSDML proteins in 24 kinds
of cell lines by Western blot with anti-GSDML polyclonal antibody. β -Actin levels were analyzed and shown as an internal control.
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Figure 2. Subcellular localization analysis of GSDML. (A) The GFP empty vector, GFP-GSDML 1, 2, 3, and 4 and GFP-GSDML-ΔNLS, were
each transfected into MCF7 cells. Twenty-four hours later, cell nuclei were stained with PI (red), and fluorescence was visualized using a
confocal microscope and images were captured and merged. Scale bar, 10 μm. (B) Indirect immunofluorescence analysis with anti-myc
antibodies (left panels) was performed to analyze the localization of GSDML after transfecting MCF7 cells with myc-GSDML 1, 2, 3, and
4. Hoechst (blue) staining (middle panels) indicates the location of nuclei in each field. The fluorescence was visualized using fluores-
cence microscope, and images were captured and merged (right panels). (C) Indirect immunofluorescence analysis with anti-GSDML
polyclonal or monoclonal (left panels) was performed to determine the localization of endogenous GSDML in the indicated cells. (D and
E) GFP-GSDML1 was transfected into HeLa (D) and HepG2 (E) cells, respectively. Twenty-four hours later, cell nuclei were stained with
PI (red), and the fluorescence was visualized using confocal microscope and images were captured and merged.
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5′-noncoding region of GSDML was 71 bp in length, and the 3′-non-
coding region was 235 bp in length. The 3′-terminus of the sequence
contained a typical poly(A) addition signal, ATTAAA, which precedes
multiple A nucleotides at the end of the sequence. The initiating ATG
codon (nucleotides 72–74) is preceded by a TGA stop codon triplet
upstream and conformed to a consensus initiation sequence. GSDML
contains a gasdermin domain (amino acids 4–374), and a putative nu-
clear localization signal (NLS) was found within the gasdermin domain
(242KEKLEDMESVLKDLTEEKRK261).
Cloning of GSDML Gene
Human GSDML gene was cloned from human fetal liver cDNA
library. Interestingly, different-length DNA fragments were observed
(Figure 1B), and the insert fragments were sequenced to be 1212,
1100, 1127, and 958 bp encoding 403, 203, 200, and 183 amino
acid polypeptides, respectively. We thus named them GSDML1,
GSDML2, GSDML3, and GSDML4 (GenBank Accession Nos.
EU526753, EU526754, EU526755, and EU526756). Nucleotide
and deduced amino acid sequence of four isoforms of GSDML were
aligned by CLUSTAL W (http://www.ebi.ac.uk/Tools/clustalw/)
(Figure W1).
Analysis of GSDML Expression in 16 Types of Cell Lines
Total RNA was extracted from 16 cell lines including 15 types of
cancer cell lines and HEK293 human embryonic kidney cells. Re-
verse transcription–polymerase chain reaction amplification was per-
formed to detect the expression of GSDML. Specific primers were
designed to detect each of these four isoforms of GSDML (666,
555, 581, and 413 bp corresponding to GSDML 1, 2, 3, and 4, re-
spectively). Except for H1299, LoVo, and HL60, all examined cell
lines showed the expression of GSDML isoforms (Figure 1C ).
Western Blot Analysis of Endogenous GSDML in 24 Cell Lines
To detect endogenous GSDML proteins, anti-GSDML polyclonal
and monoclonal antibodies were generated. All four ectopic ex-
pressed isoforms of GSDML could be detected by rabbit anti-
GSDML polyclonal antibody and mouse anti-GSDML monoclonal
antibody (Figure 1D). Using the specific anti-GSDML polyclonal anti-
body, we observed that GSDML1 is widely expressed in the human
cancer cell lines we examined (except Jurkat, Molt4, HL60, and
HEK293), whereas the three short isoforms of GSDML could not
be detected remarkably in the total 24 cell lines (Figure 1E). Notably,
GSDML protein is expressed at a higher level in the metastatic ade-
noid cystic carcinoma (ACC) cell line ACC-M than in the nonmeta-
static cell line ACC-2.
Subcellular Localization Analysis of GSDML
As shown in Figure 2A, GFP-GSDML1 protein was localized pri-
marily in the nucleus and partly in the cytoplasm, whereas GFP-
GSDML 2 and 3 were distributed in the cytoplasm. We also noted
that in some cells, the transfection of GFP-GSDML1 seems to pro-
mote rounding of cells, and therefore, the fluorescence signal appears
rounded. Sequence analysis showed that a basic amino acid–rich se-
quence KEKLEDMESVLKDLTEEKRK (242–261aa, basic residues
are underlined) is predicted to be the putative NLS of GSDML. To
verify this hypothesis, GFP-GSDML1-ΔNLS was constructed, and
we observed that GFP-GSDML1-ΔNLS was distributed thoroughly
in the cytoplasm. These results suggest that this sequence is indeed
required for the nuclear localization of GSDML1. Although lacking
the NLS within GSDML1, GFP-GSDML4 could be still localized
primarily in the nucleus and partly in the cytoplasm (vesicular stain-
ing) or plasma membrane. We considered that newly formed basic
amino acid–rich sequence by exon-skipping frameshift among the
C-terminal of GSDML4 protein might play a role in its nuclear lo-
calization. To confirm the conclusions of the localization of GFP-
tagged GSDML isoforms, myc-tagged GSDMLs were expressed in
MCF7 cells, and their subcellular localization was determined by in-
direct immunofluorescence analysis with anti-myc antibody. The re-
sults coincided with those of GFP-GSDMLs (Figure 2B).
We next investigated the subcellular localization of the endoge-
nous GSDML protein. In MCF7 breast cancer cells, endogenous
GSDML was localized mainly in the nucleus and partly in the cyto-
plasm as determined by indirect immunostaining with anti-GSDML
polyclonal antibody and confirmed by anti-GSDML monoclonal anti-
body (Figure 2C , top two panels). In addition, HeLa, HepG2, and
LoVo cell lines were also applied to subcellular localization analysis
of endogenous GSDML. Surprisingly, although GSDML was in the
nucleus of HeLa cervix cancer cells (Figure 2C , middle panels), which
was similar to that in MCF7 cells, endogenous GSDML was exclu-
sively cytoplasmic in HepG2 hepatocellular carcinoma cells and LoVo
colorectal adenocarcinoma cells (Figure 2C , bottom two panels). Con-
sistent with the endogenous data, GFP-tagged GSDML1 protein was
also localized in nucleus of HeLa cells (Figure 2D) but exclusively in
the cytoplasm of HepG2 cells (Figure 2E). These results suggested that
the localization of GSDML1 not only was determined by nuclear lo-
calization signal but was also dependent of tissue and cell types. There-
fore, we next explore whether GSDML is involved in carcinogenesis of
uterine cervix cancer and hepatocellular carcinoma.
Correlation of Clinical Features with GSDML Expression
According to exogenous GFP-GSDML1 localized in the nucleus
of HeLa cells, GSDML expression in the nucleus (including exclu-
sively and partially nuclear) was considered as GSDML-positive,
whereas expression in the cytoplasm or undetectable expression
was considered as GSDML-negative. Among 21 uterine cervix cancer
samples tested, 16 (76.2%) were GSDML-positive and 5 (23.8%)
were GSDML-negative. Among 21 adjacent cancer tissues, 8 (38%)
were GSDML-positive and 13 (61.9%) were GSDML-negative.
Figure 3. GSDML protein expression in uterine cervix cancer and hepatocellular carcinoma tissue microarrays. (A) Immunohistochem-
istry staining of GSDML expression in uterine cervix cancer (top), adjacent cancer tissues (middle), and corresponding nonneoplastic
tissues (bottom). Immunohistochemistry analyses with negative control are shown in the left panels and with antibodies against GSDML
are in the right panels. The expression of GSDML in nucleus was considered GSDML-positive, whereas expression in cytoplasm or no
expression was considered GSDML-negative. Original magnification, ×400. (B) Immunohistochemistry staining of GSDML expression in
hepatocellular carcinoma (top), adjacent cancer tissues (middle), and corresponding nonneoplastic tissues (bottom). The experiments
were performed and the results were shown similar to (A).
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Among 21 corresponding nonneoplastic tissues with cancers, 8
(38%) were GSDML-positive and 13 (61.9%) were GSDML-negative.
Representative examples of GSDML-positive and -negative tumors
are shown in Figure 3A. Statistical analysis was done to determine
whether a possible correlation occurred between GSDML expression
and clinical variables (Table 1). Immunohistochemistry with uterine
cervix cancer tissue microarray revealed that the number of GSDML-
positive cases was significantly larger in uterine cervix cancer than in
adjacent cancer tissues (P < .05) and in corresponding nonneoplastic
tissues with cancers (P < .05). Among 21 adjacent cancer tissues and
21 corresponding nonneoplastic tissues with cancers, there are 27
cervicitis (including two atypical hyperplasia), 1 cancer tissue, and
14 normal tissues. Nuclear staining of GSDML was found in
72.7% (16/22) of the cancer samples, in 42.3% (11/26) of cervicitis
samples, and in 33.3% (5/15) of normal samples. GSDML protein
levels were significantly higher in uterine cervix cancer tissue than in
cervicitis (P < .05) and in normal tissue (P < .05).
Hepatocellular carcinoma patients were then further analyzed.
Among 21 hepatocellular carcinoma patients, 2 cases (9.5%) were
nuclear staining, 15 cases (71.4%) were cytoplasm staining, and
4 cases (19%) were none staining. All of 21 adjacent cancer tissues
were cytoplasm staining (100%). Among 21 corresponding nonneo-
plastic tissues with cancers, 19 cases (90.5%) were cytoplasm staining
and 2 cases (9.5%) were none staining. According to exogenous
GFP-GSDML1 localized in the cytoplasm of HepG2 cells, the ex-
pression of GSDML in the cytoplasm and/or in the nucleus was con-
sidered GSDML-positive (Figure 3B). Statistical analysis was done to
determine whether a possible correlation occurred between GSDML
expression and clinical variables (Table 2). There was no statistically
significant difference between the expression levels in the hepatocel-
lular carcinoma, adjacent cancer, and the corresponding nonneoplas-
tic tissues. Overexpression of GSDML was found in 81% (17/21) of
the cancer samples, in 100% (14/14) of hepatic cirrhosis samples, in
100% (9/9) of inflammation/hyperplasia/adipose degeneration sam-
ples, and in 89.5% (17/19) of normal samples. There was no statis-
tically significant difference between the expression levels in the
hepatocellular carcinoma, hepatic cirrhosis, inflammation/hyperplasia/
adipose degeneration, and normal tissue (P > .05).
GSDML Stimulates Cell Proliferation of Ovarian and Cervix
Cancer Cell Lines
Next, we investigated whether GSDML1 had any effects on cell
growth. To prevent the interference of endogenous human GSDML
proteins, Chinese hamster ovarian cells (CHO-K1) without endoge-
nous GSDML expression (Figure W2A) were used instead of HeLa
cells to screen GSDML1 stably expressing transfectants. GFP-
GSDML1 was localized predominantly in the nucleus and also seen
in the cytoplasm (Figure W2B), which was similar to that in HeLa
cells. Stable transfection of GSDML1 promoted the cell growth in
CHO-K1 cells (Figure 4A). The promotion became obvious from
the third day and increased thereafter. There was a significant differ-
ence between the three individual GSDML1-expressing cells and the
empty vector control group (P < .01).
To analyze further the effect of GSDML on cellular proliferation,
BrdU incorporation assay was applied to measure the rates of DNA
synthesis. GSDML1 had significant effects on promoting BrdU in-
corporation in CHO-K1 cells (clone A, P < .01; clones B and C, P <
.05; Figure 4B).
We next used siRNA to evaluate the role of endogenous GSDML in
the cell proliferation of HeLa and HepG2 cell lines. We identified a
siRNA to be efficient in inhibiting GSDML in HeLa and HepG2.
MTT assays showed that HeLa cells transfected with GSDML siRNA
exhibited a significant decrease in cell growth compared with those
with the negative control siRNA (Figure 4C). By contrast, in HepG2
cells, there was no significant difference in cell growth between the
cells transfected with the GSDML1 siRNA and with the negative con-
trol siRNA (Figure 4D).
Figure 4. Effects of overexpression and knock down of GSDML on cell proliferation. (A) Growth rates of CHO-K1 cells stably transfected
with either GSDML1 expression vector (CHO-GSDML1) or empty vector (CHO-EV) were measured by MTT assays. Points indicate mean
of quadruplicate samples; bars, SD. Western blot analysis of the indicated proteins in CHO-GSDML1 and CHO-EV cells are shown below
to confirm the expression. (B) Proliferation of CHO-K1 cells stably transfected with either GSDML1 expression vector (CHO-GSDML1)
or empty vector (CHO-EV) was measured by BrdU incorporation. Columns indicate means of three independent experiments; bars, SD.
**P < .01; *P < .05, statistically significant. (C and D) MTT assays. Growth rates of HeLa (C) and HepG2 (D) cells with transfection of
GSDML1 siRNA and negative control siRNA. Points indicate mean of quadruplicate samples; bars, SD. Cells were harvested daily and
analyzed by Western blot for GSDML1 expression. β -Actin was used as control for equal loading and siRNA specificity. (E) HeLa and
HepG2 cells were transfected with either short hairpin RNA (shRNA) construct targeting GSDML1 gene (sh-GSDML) or shRNA empty
vector (sh-EV), respectively. Thirty-six hours later, cells were harvested and analyzed by Western blot for GSDML1 expression. β-Actin
was used as control for equal loading and shRNA specificity. (F) Forty-eight hours after transfection with either sh-GSDML1 or sh-EV, the
HeLa and HepG2 cells were selected with G418 for 3 weeks.
Table 1. Relationship between Expression Levels of GSDML and Uterine Cervix Cancer.
Clinical Characteristics GSDML-Negative GSDML-Positive P
Sample
Cancer tissues 5 16
Adjacent cancer tissues 13 8 .028*
Corresponding nonneoplastic tissues with cancers 13 8 .028*
Histopathologic type
Cancer 6 16
Cervicitis 15 11 .045*
Normal 10 5 .017*
*Statistically significant.
Table 2. Relationship between Expression Levels of GSDML and Hepatocellular Carcinoma.
Clinical Characteristics GSDML-Negative GSDML-Positive P
Sample
Cancer tissues 4 17
Adjacent cancer tissues 2 19 .663
Corresponding nonneoplastic tissues with cancers 0 21 .107
Histopathologic type
Cancer 4 17
Cirrhosis 0 14 .133
Inflammation, hyperplasia, or adipose degeneration 0 9 .114
Normal 2 17 .664
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Furthermore, knock down of GSDML1 in HeLa cells showed that
the number of G418-resistant colonies was significantly reduced, sug-
gesting that GSDML was essential for cell growth and that its defi-
ciency could result in growth retardation (Figure 4E ). Similar to the
previously mentioned conclusions, this effect could not be observed
in HepG2 cells (Figure 4F ).
GSDML1 Could Not Induce Malignant Transformation of
CHO-K1 Cells
Evaluation of colony-forming efficiency in soft agar and carcinogenic
ability on nude mice models was performed to determine whether
GSDML1 possesses a potency of malignant transformation. Both
CHO-K1 cells transfected with GSDML1 and control vector failed
to form colony in soft agar. Coincidentally, the CHO-K1 cells trans-
fected with GSDML1 and control vector into the nude mice failed to
produce tumors (Table 3).
Discussion
The GSDMDC family is a novel protein superfamily, characterizing
a gasdermin domain in all of members. Although a few studies indi-
cated that the GSDMDC family had important physiological func-
tions in development, tumorigenesis, and genetic disease with deafness
and hair loss phenotype, the molecular structure and precise biologic
function of GSDMDC family are still unclear [1–5,7,8,13–15]. The
relationship between GSDMDC family members and carcinogenesis
has been suggested. The DFNA5 and GSDM have a negative corre-
lation with carcinogenesis, whereas the MLZE and DFNA5L have a
positive correlation with carcinogenesis [2–4,7,8]. More studies have
focused on the DFNA5 gene because it is one of the disease genes
with an autosomal-dominant nonsyndromic hearing impairment
and it is associated with melanoma, breast cancer, and gastric cancer
[6–8]. Morpholino antisense nucleotide knock down of DFNA5 func-
tion in zebrafish leads to the disorganization of the developing semicir-
cular canals and to the reduction of pharyngeal cartilage, indicating that
DFNA5 is required for the normal development of the ear [16]. Mor-
phologic studies demonstrated significant differences in the number of
fourth-row outer hair cells between Dfna5−/− mice and their wild type
littermates [13]. Extensive expression analysis revealed an exclusive
expression of the GSDM gene in the epithelium of the skin and gas-
trointestinal tract in a highly tissue-specific manner. Loss of the ex-
pression of the human GSDM is required for the carcinogenesis of
gastric tissue, and this gene has an activity adverse to malignant trans-
formation of cells [4,9]. Gsdm3 (mouse homolog of GSDM) muta-
tions cause alopecia in Rco2, Re(den), and Bsk mice, showing that the
murine Gsdm3 gene is required for the normal development and cy-
cling of the dorsal hair follicle, the epidermis, and the development of
sebaceous glands from the pilosebaceous unit [14]. Pejvakin gene, a
newly identified member of the GSDMDC family, in which two mis-
sense mutations cause nonsyndromic recessive deafness (DFNB59)
by affecting the function of auditory neurons [17]. Another study
has described a premature stop codon of pejvakin gene, causing outer
hair cell defects and leading to progressive hearing loss, suggesting
that pejvakin genes control the development and function of me-
chanosensory hair cells and cause deafness [18]. Current data suggest
that physiological functions of the GSDMDC family are possibly in-
volved in the development and differentiation of epithelial cells.
To find new cancer-associated genes in the GSDMDC family, we
cloned GSDML gene from a human fetal liver cDNA library. As a
novel member of the GSDMDC family, however, the function of
the GSDML gene remains unknown. The GSDML gene is mapped
to 17q21.2, a region that contains the erbB2 gene and is often am-
plified in malignant tumors [5]. The full-length cDNA of GSDML is
1518 bp long and contains an open reading frame from nucleotide
72 to nucleotide 1283 capable of encoding a 403–amino acid poly-
peptide with a predicted molecular mass of 46 kDa. GSDML protein
contains a gasdermin domain within which a putative nuclear local-
izing signal was identified (Figure 2). Interestingly, we also isolated
three short splicing isoforms of GSDML. The solitary long terminal
repeats (LTRs) of human endogenous retroviruses (HERVs) have
been found to serve as alternative promoters of the GSDML gene
[19]. The HERV-H LTR element on the GSDML gene was integrated
into the genome of hominoid primates. Such an LTR element seems
to be active as the dominant promoter in human tissues and cancer
cells. Western blot analysis with the specific anti-GSDML polyclonal
antibody showed that GSDML1 is widely expressed in human cancer
cell lines we examined, whereas the three short isoforms of GSDML
were not detected clearly in all the 24 cell lines tested. The nonsense-
mediated decay pathway is an mRNA surveillance mechanism that
limits the translation of mRNA with premature termination codons
[20,21]. Alternative splicing of GSDML is subject to the mode of
exon-skipping frameshift with premature termination codons. We
presumed that the three short isoforms of the GSDML protein were
inhibited by nonsense-mediated decay pathway. Hence, the full-
length GSDML1 protein became the focal point of study. Nguyen
et al. [22] investigated the differences in gene expression profiles be-
tween primary tumors of oral squamous cell carcinoma that had
metastasized to cervical lymph nodes and those that had not metas-
tasized in the hope of finding new biomarkers to serve for diagnosis
and treatment of oral cavity cancer by microarray technology. Ulti-
mately, eight candidate genes expressed differentially were selected to
achieve the minimum error rate. Among them, the GSDML gene is
one of six up-regulated genes in oral cavity cancer with the cervical
lymph node metastasis. Correspondingly, the expression levels of
ACC-M (adenoid cystic carcinoma cell clones highly metastatic to
the lung) are significantly higher than that in ACC-2 (adenoid cystic
carcinoma cell line, ACC-2) in our study (Figure 1D). Overexpres-
sion of GSDML in ACC-M suggested that GSDML may be involved
in tumor metastasis.
In the present investigation, we have shown that the subcellular
localization of GSDML1 was different in different tissues and cell
lines. GFP-GSDML1 localized predominantly in the nucleus of
HeLa cells, but unexpectedly, localized in the cytoplasm of HepG2
cells. Interestingly, nuclei staining of the GSDML protein was ex-
pressed at a higher level in uterine cervix cancer tissue than in the
adjacent cancer tissues and corresponding nonneoplastic tissues
through immunohistochemistry analysis of cancer tissue microarray
(Figure 3A). In addition, nuclei staining levels of GSDML protein
were significantly higher in uterine cervix cancer tissue than in cer-
vicitis and normal tissue. As in most hepatocellular tissues samples,
Table 3. CHO Cell Lines Colony-Forming and Tumorigenic Ability.
Stable Cell Lines Colony-Forming Units Animals with Tumor at 21 days
Empty vector 0/3* 0/4†
GSDML 1 0/3* 0/4†
*Number of colony-forming units/number of planted wells.
†Number of animals with subcutaneous tumor/number of injected animals.
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GSDML was cytoplasm staining; such difference has not been ob-
served in hepatocellular carcinoma tissues microarray (Figure 3B),
suggesting that the effect of GSDML may be different in different
tissues as determined by subcellular localization. Among 63 hepatic
tissue samples, the only 2 cases of nuclei staining are all hepatocellu-
lar carcinoma. We observed that there are still a few proportions of
GSDML-positive in cervicitis and normal tissue, suggesting that
GSDML could be important as an evaluation indicator in onset risk
during the normal to cervicitis to lesion precancerous to uterine cer-
vix cancer transition process.
We found exogenous GSDML1-stimulated proliferation of
CHO-K1 cells by the growth curve and BrdU incorporation assay.
Furthermore, knock down of endogenous GSDML1 in HeLa cells
could result in growth retardation, but such results could not been
observed in HepG2 cells through several experimental models. We
presume that the difference in the effect of GSDML1 may correlate
with its subcellular localization. Study on the localization of GFP-
GSDML1 in more cell lines showed that GFP-GSDML1 was local-
ized mainly in the nucleus of MCF7, T47D, HeLa, Ishikawa,
and CHO-K1 cell lines and in the cytoplasm of HepG2, N87,
SW480, and U2OS cell lines (data not shown). The results also im-
ply that GSDML may be involved in the progression of cancer in the
female reproductive system. Although GSDML1 can stimulate pro-
liferation of cells through nuclear localization, colony formation assay
and tumorigenic assay on nude mice revealed that GSDML could
not induce malignant transformation of cells, implying that GSDML
may not be used as a proto-oncogene.
To investigate the molecular mechanism, we hypothesized that
GSDML1 might interact with nuclear receptors because it contains
two LXX(L/I)L motifs (amino acids 58–62 and 325–329) that have
been found to be necessary and sufficient for interaction with the
nuclear receptor [23,24]. Knock down of endogenous GSDML ex-
pression by siRNA led to the reduced activity of estrogen receptor
alpha (ERα) and the sensitivity of ERα to estrogen ligand, suggesting
that GSDML may be involved in the regulation of ERα activity
in vivo (our unpublished data).
Taken together, we have cloned and characterized GSDML, a novel
member of the GSDMDC family. The structure, tissue/cell expression
profiling, and subcellular localization of GSDML were characterized.
Our study revealed the role of GSDML in tumorigenesis of the uterine
cervix cancer and its potential mechanism, contributing to the full un-
derstanding of the GSDMDC family. These results also provide the
first evidence that GSDML can exert different effects on the basis of
different subcellular localization, supplying new clues for elucidating
the GSDMDC family’s function.
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Figure W1. Nucleotide sequence and deduced amino acid sequence of the GSDML 1, 2, 3, and 4. (A) Four isoforms of GSDML cDNA
sequence alignment. The four stop codons are boxed. (B) Four isoforms of GSDML protein sequence alignment.
Figure W2. Subcellular localization analysis of GSDML1 in CHO-K1 cells. (A) Endogenous expression of GSDML proteins was undetect-
able in CHO-K1, COS7, and NIH3T3 cell lines. Western blot analysis with GSDML antibody and β-actin antibody was performed. Cell
lysate expressing Myc-tagged GSDML1 proteins was loaded as a positive control. (B) The GFP empty vector and GFP-GSDML1 were
each transfected into CHO-K1 cells. Twenty-four hours later, cell nuclei were stained with Hoechst, and the fluorescence was visualized
using a fluorescence microscope and images were captured and merged.
